UCL Cancer Institute


Current Trials



 

How to Refer a Patient for Phase I Assessment

Email:  phase1cancer@uclh.nhs.uk   Telephone: +44 (0)20 3447 6036

Post:  Todd Gumbleton, Sr. Research Nurse, Clinical Research Facility, EGA Wing, UCH,
235 Euston Road London NW1 2BU

 







Drug Class EudraCT Id* Study full title Principle Investigator
  *Search EudraCT Id info here: https://www.clinicaltrialsregister.eu/ctr-search/search
Generic
PI3K and mTOR inhibitor 2013-001390-24 A phase 1b open-label , multi-center study to assess the safety and tolerability of PF-05212384 in combination with a variety of anti-tumor agents Dr Kristeleit
PARPi 2013-002246-37 An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study to Determine the Pharmacokinetics, Safety and Tolerability of Olaparib following a Single Oral 300 mg Dose to Patients with Advanced Solid Tumours and Normal Hepatic Function or Mild or Moderate Hepatic Impairment Dr Kristeleit
pan-PI3K and mTOR inhibitor 2013-003441-42 Phase I study of oral PQR309 in Patients with Advanced Solid Tumours Dr Kristeleit
cytotoxic
non-taxane microtubule dynamics inhibitor
2012-001184-69 An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients with Solid Tumors Dr Kristeleit
Synthetic alkylating agent 2010-024291-25 Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination with Doxorubicin in Non-heavily Pretreated Patients with Selected Advanced Solid Tumors Dr Forster
IV Microtubule inhibitor. Novel mechanism 2010-024237-23 An Open-Label Phase I/IIa Study of Intravenous BAL101553 in Adult Patients with Advanced Solid Tumors Dr Kristeleit
Haematology
IL3-receptor Ab 2013-003657-21 FiM Anti-IL-3Ra (CD123) mAb; fully-human IgG1 for patients with previously untreated AML , relapsed/refractory AML, relapsed/refractory MDS or MDS who are not candidates to receive a hypomethylating agent Dr Popat
humanized IgG1 antibody drug conjugate (ADC) 2003-004549-18 A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Subjects with Relapsed/Refractory Multiple Myeloma and Other Advanced Hematologic Malignancies Expressing BCMA Dr Popat
Proteasome inhibitor 2013-002302-32 An Open-Label, Multicenter, Phase 2 Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Follicular Lymphoma Dr Popat
JAK inhibitor + PI3K inhibitor 2012-003385-41 A phase Ib, open-label, multi-center, two-arm, dose-finding study to assess the safety and efficacy of the oral combination of Ruxolitinib (INC424) and BKM120 in patients with primary myelofibrosis (PMF), postpolycythemia vera-myelofibrosis (PPV-MF), or postessential thrombocythemia-myelofibrosis (PET-MF) Dr Popat
VTD associated with inhibitor (DACi) 2012-000842-36 A Phase I/IIa trial of VTD-panobinostat treatment and panobinostat maintenance in relapsed and relapsed/refractory multiple myeloma patients Prof Yong
HDACi 2011-001914-33 A Phase I/IIa, Dose-Escalation, Study of CHR-3996 in Combination with Tosedostat in Participants with Relapsed, Refractory Multiple Myeloma Prof Yong
Next-Generation Proteasome Inhibitor 2010-023772-71 An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of MLN9708, a Next-Generation Proteasome Inhibitor, Administered in Combination With a Standard Care Regimen of Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment Prof Yong
Gastro-Intstinal
Anti-VEGF 2013-002308-15 A phase I/II dose finding study evaluating the safety and tolerability of CAPecitabine and AflIbercept in patients with unresectable metasTAtic colorectaL cancer deemed unsuitable for doublet/ triplet chemotherapy.                  Dr Bridgewater
HER 1,2 3 inhibitor 2012-005111-12 Molecular selection of therapy in metastatic colorectal cancer: a molecularly stratified randomised controlled trial programme
FOCUS4-D testing AZD8931 (a HER 1,2 3 inhibitor) against placebo in patients stratified into the All wild-type cohort
Dr Bridgewater
inhibitor of EGFR, ERBB2 and ERBB3  2012–002811–25 AZD8931, an inhibitor of EGFR, ERBB2 and ERBB3 signalling, in combination with FOLFIRI: A Phase I/II study to determine the importance of schedule and activity in colorectal cancer Prof Hochhauser
Hepathobiliary
HDACi 2012-000326-22  A Phase I/II dose escalation trial of HDAC inhibitor tefinostat (CHR- 2845) for cancer associated inflammation in hepatocellular carcinoma Prof Meyer
PARPi 2013-002246-37 An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study to Determine the Pharmacokinetics, Safety and Tolerability of Olaparib following a Single Oral 300 mg Dose to Patients with Advanced Solid Tumours and Normal Hepatic Function or Mild or Moderate Hepatic Impairment Dr Kristeleit
Lung
HSP90 inhibitor 2012-001598-10 A phase I/II study of first line ganetespib with pemetrexed/cisplatin, in patients with malignant pleural mesothelioma Dr Forster
Hedgehog/SMO Antagonist 2012-003174-83 A Phase 1b/2 Double-Blind Randomized Trial of the
Hedgehog/SMO Antagonist LY2940680 in Combination with Carboplatin and Etoposide Followed by LY2940680 versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients with Extensive-Stage Small Cell Lung Cancer
Dr Forster
Gynae
Novel potent selective IDO1 enzyme inhibitor 2012-001472-10 A randomized, open-label, Phase 2 study of the IDO inhibitor INCB024360 versus tamoxifen for subjects with biochemical-recurrent-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer following complete remission with first-line chemotherapy Dr Kristeleit



Page Last Modified: 28 July 2014